Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer

Study limitation reported by the research below: “Brand name 'Datroway' (FDA-approved name for datopotamab deruxtecan) used; paper uses non-proprietary name only.”